Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Search Videos by Topic or Participant
Browse by Series:

Assessing Response to Imatinib in GIST

Insights From: Robert Hans Ingemar Andtbacka, MD, CM, Huntsman Cancer Institute ; Anthony P. Conley, MD, The University of Texas MD Anderson Cancer CenterSyma Iqbal, MD, UCS Norris Comprehensive Cancer Center and Hospital
Published: Tuesday, Dec 01, 2015


In a seminal study that assessed the efficacy of imatinib in patients with gastrointestinal stromal tumor (GIST), those with tumors 3 centimeters or larger were randomized to receive placebo or imatinib. The study showed a significant improvement in recurrence-free survival with imatinib, says Syma Iqbal, MD. However, a large limitation of this study was that it did not take into account the mitotic rate of the tumor.

Another study evaluating imatinib enrolled patients with high-risk features at baseline, explains Anthony P. Conley, MD. These individuals had tumors greater than 10 centimeters, high mitotic rates, or tumor rupture. Results showed a greater survival benefit in the cohort that received 3 years of imatinib compared with those who received 1 year of imatinib. While these findings altered treatment approaches with respect to duration of therapy in patients with high-risk GIST, the optimal length of treatment remains unclear, says Iqbal. Some clinical trials have assessed the use of up to 5 years of imatinib in the adjuvant setting, adds Conley.

Patients who have undergone surgical resection of their GIST should be followed on a regular basis with physical examination and cross-sectional imaging with a CT scan of the abdomen and pelvis, if the tumor is located in the abdomen, and a CT scan of the chest for esophageal GIST, recommends Robert H. I. Andtbacka, MD. These scans should be performed every 3 to 6 months, as per National Comprehensive Cancer Network recommendations.

The scans may reveal solid tumors that have metastasized to the liver or those that have decreased in density and vascularity following surgical resection and adjuvant treatment, says Andtbacka. Individuals who have tumor recurrence typically undergo tumor biopsy to determine the mutational status of the malignancy.

Andtbacka and his colleagues often utilize immunohistochemical analysis and staining to test for c-KIT, DOG1, protein kinase C-theta, and platelet derived growth factor receptor, as well as mutations in exon 9, 11, 13, and 17. How patients respond to treatment depends on these mutations, comments Andtbacka.
Slider Left
Slider Right


In a seminal study that assessed the efficacy of imatinib in patients with gastrointestinal stromal tumor (GIST), those with tumors 3 centimeters or larger were randomized to receive placebo or imatinib. The study showed a significant improvement in recurrence-free survival with imatinib, says Syma Iqbal, MD. However, a large limitation of this study was that it did not take into account the mitotic rate of the tumor.

Another study evaluating imatinib enrolled patients with high-risk features at baseline, explains Anthony P. Conley, MD. These individuals had tumors greater than 10 centimeters, high mitotic rates, or tumor rupture. Results showed a greater survival benefit in the cohort that received 3 years of imatinib compared with those who received 1 year of imatinib. While these findings altered treatment approaches with respect to duration of therapy in patients with high-risk GIST, the optimal length of treatment remains unclear, says Iqbal. Some clinical trials have assessed the use of up to 5 years of imatinib in the adjuvant setting, adds Conley.

Patients who have undergone surgical resection of their GIST should be followed on a regular basis with physical examination and cross-sectional imaging with a CT scan of the abdomen and pelvis, if the tumor is located in the abdomen, and a CT scan of the chest for esophageal GIST, recommends Robert H. I. Andtbacka, MD. These scans should be performed every 3 to 6 months, as per National Comprehensive Cancer Network recommendations.

The scans may reveal solid tumors that have metastasized to the liver or those that have decreased in density and vascularity following surgical resection and adjuvant treatment, says Andtbacka. Individuals who have tumor recurrence typically undergo tumor biopsy to determine the mutational status of the malignancy.

Andtbacka and his colleagues often utilize immunohistochemical analysis and staining to test for c-KIT, DOG1, protein kinase C-theta, and platelet derived growth factor receptor, as well as mutations in exon 9, 11, 13, and 17. How patients respond to treatment depends on these mutations, comments Andtbacka.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x